COVID-19 mRNAワクチンによる障害報告のレビュー：アナフィラキシー

Dr Mark Trozzi（マーク・トロッツィ博士）がCOVID-19 mRNAワクチンによる障害報告に関する査読済み論文の約1,000件を掲載したサイトを作っています。

1000 peer reviewed articles on “Vaccine” injuries

その中で8番目に多くの件数が報告されている「アナフィラキシー（Anaphylaxis）」の論文リストを転載させていただきます。

アナフィラキシー状態。生命を脅かす可能性のある重篤なアレルギー反応。国内では、アナフィラキシーを起こした人の９割以上は女性でした。使われている米ファイザー製と米モデルナ製のワクチンには、ポリエチレングリコール（ＰＥＧ）が含まれています。化粧品の成分にもなる化合物です。これがアナフィラキシーの原因物質となっている可能性があります。
顔色不良、口周囲チアノーゼ、不活発（声を出さなくなる）。顔面チアノーゼ（軽微）が発現した実績があります。

掲載論文数:30

COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization: 
https://www.sciencedirect.com/science/article/pii/S1939455121000119
.
Allergic reactions, including anaphylaxis, after receiving thefirst dose of the Pfizer-BioNTech COVID-19 vaccine: 
https://pubmed.ncbi.nlm.nih.gov/33475702/

Allergic reactions, including anaphylaxis, after receiving thefirst dose of Pfizer-BioNTech COVID-19 vaccine ? United States, December 14-23, 2020: 
https://pubmed.ncbi.nlm.nih.gov/33444297/

Allergic reactions, including anaphylaxis, after receivingfirst dose of Modern COVID-19 vaccine ? United States, December 21, 2020-January 10, 2021: 
https://pubmed.ncbi.nlm.nih.gov/33507892/

Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: 
https://pubmed.ncbi.nlm.nih.gov/34414880/

Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/

Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: 
https://pubmed.ncbi.nlm.nih.gov/34269740/

Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34215453/

Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: 
https://pubmed.ncbi.nlm.nih.gov/33932618/

Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: 
https://pubmed.ncbi.nlm.nih.gov/33571463/

Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: thefirst month report: 
https://pubmed.ncbi.nlm.nih.gov/34347278/

COVID-19 vaccines increase the risk of anaphylaxis:
https://pubmed.ncbi.nlm.nih.gov/33685103/

Biphasic anaphylaxis after exposure to thefirst dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: 
https://pubmed.ncbi.nlm.nih.gov/34050949/

Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: 
https://pubmed.ncbi.nlm.nih.gov/33825239/

Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: 
https://pubmed.ncbi.nlm.nih.gov/34128049/

.IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: 
https://pubmed.ncbi.nlm.nih.gov/34318537/

Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: 
https://pubmed.ncbi.nlm.nih.gov/33846043/ 188
.
Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: 
https://pubmed.ncbi.nlm.nih.gov/33851711/

Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: 
https://pubmed.ncbi.nlm.nih.gov/34675550/

Anaphylaxis after Modern COVID-19 vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34734159/

Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: 
https://pubmed.ncbi.nlm.nih.gov/34020815/

Allergic reactions, including anaphylaxis, after receiving thefirst dose of Pfizer-BioNTech COVID-19 vaccine ? United States, December 14 to 23, 2020: 
https://pubmed.ncbi.nlm.nih.gov/33641264/

Allergic reactions, including anaphylaxis, after receiving thefirst dose of Modern COVID-19 vaccine ? United States, December 21, 2020 to January 10, 2021: 
https://pubmed.ncbi.nlm.nih.gov/33641268/

Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: 
https://pubmed.ncbi.nlm.nih.gov/33834172/

Anaphylaxis reactions to P? zer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: 
https://pubmed.ncbi.nlm.nih.gov/34579211/

Biphasic anaphylaxis afterfirst dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: 
https://pubmed.ncbi.nlm.nih.gov/34343674/

Biphasic anaphylaxis after exposure to thefirst dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: 
https://pubmed.ncbi.nlm.nih.gov/34050949/

Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9 
https://www.ncbi.nlm.nih.gov/pubmed/34347278

Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine ? United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. 
https://www.ncbi.nlm.nih.gov/pubmed/33444297

さらにひどい症状だとアナフィラキシーショックがあり、複数の臓器に症状がみられます。
〈１〉皮膚、粘膜症状（全身の発疹やかゆみ、口や舌のただれ）
〈２〉呼吸器症状（呼吸困難、強いせきなど）
〈３〉循環器症状（血圧低下、意識障害）
〈４〉消化器症状（ 嘔吐おうと 、下痢など）

自己抗体（Autoantibody）

自己抗体（Autoantibody）のページを作成中

　自己抗体（Autoantibody）とは、自己の細胞ないし組織に対して産生される抗体のこと。

抗体とは本来、体に入り込んだ異物（細菌やウイルスなど）を攻撃したり、体の外に排出したりするはたらきを担うたんぱく質で、自分自身を攻撃するためにつくられるものではありません。 しかし、体内の成分が異物と勘違いされたり、異物と似た物質に変質してしまうことで、自分自身の体に対してはたらき、ダメージを及ぼす抗体がつくられてしまうことがあります。

自己抗体の産生は，遺伝子的素因，ホルモン，治療薬，環境因子(ウイルス・毒物)などによって引き起こされると考えられています。 自己抗体は自己免疫疾患に関連しており，有用なバイオマーカーであることが示唆されています。

種類	メモ
抗核抗体（ANA）	真核細胞の核に結合する抗体群の総称
抗平滑筋抗体	平滑筋に対する自己抗体。自己免疫性肝炎で高率に検出
抗ガングリオシド抗体
肝腎ミクロソーム抗体1型
抗好中球細胞質抗体 (ANCA)
抗アミノアシルtRNA合成酵素抗体 （抗ARS抗体）
抗ミトコンドリア抗体
抗アセチルコリン受容体抗体
抗甲状腺ペルオキシダーゼ抗体
抗TSHレセプター抗体
抗NMDA抗体

　⇒　抗原と抗体

COVID-19 mRNAワクチンによる障害報告のレビュー：リンパ節症

Dr Mark Trozzi（マーク・トロッツィ博士）がCOVID-19 mRNAワクチンによる障害報告に関する査読済み論文の約1,000件を掲載したサイトを作っています。

1000 peer reviewed articles on “Vaccine” injuries

その中で7番目に多くの件数が報告されている「リンパ節症（Lymphadenopathy）」の論文リストを転載させていただきます。

リンパ節症： 片側性、鎖骨上および頸部。リンパ節の大きさに影響を及ぼす疾患。
XBBワクチン接種後に首が痛くなる例が増えているようです。ご注意ください。
血液検査では白血球数が増加し、炎症反応CRPが上がります。
リンパ節では、リンパ液から損傷した細胞、がん細胞、異物がこし取られます。リンパ節内の特殊な白血球は、損傷した細胞、がん細胞、感染性微生物、異物などを飲み込んで破壊します。
痛み、圧痛、発赤をいずれも伴わないリンパ節の腫れは、 リンパ腫、 結核、 ホジキンリンパ腫など、別の重篤な病気の症状である可能性もあります。

掲載論文数: 35

Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: 
https://pubmed.ncbi.nlm.nih.gov/34667486/

COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: 
https://pubmed.ncbi.nlm.nih.gov/33591026/

Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: 
https://pubmed.ncbi.nlm.nih.gov/33625300/

Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: 
https://pubmed.ncbi.nlm.nih.gov/33774684/

Lymphadenopathy after COVID-19 vaccination: review of imaging findings: 
https://pubmed.ncbi.nlm.nih.gov/33985872/

Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34115709/
.
COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: 
https://pubmed.ncbi.nlm.nih.gov/34257025/

Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: 
https://pubmed.ncbi.nlm.nih.gov/34280870/

COVID-19 post-vaccination lymphadenopathy: report offine-needle aspiration biopsy cytologic findings: 
https://pubmed.ncbi.nlm.nih.gov/34432391/

Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: 
https://pubmed.ncbi.nlm.nih.gov/34731748/

Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: 
https://pubmed.ncbi.nlm.nih.gov/33706861/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: 
https://pubmed.ncbi.nlm.nih.gov/34116295/

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDGfinding: 
https://pubmed.ncbi.nlm.nih.gov/33661328/

A case of cervical lymphadenopathy following COVID-19 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34141500/

Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: 
https://pubmed.ncbi.nlm.nih.gov/33713605/

Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: 
https://pubmed.ncbi.nlm.nih.gov/33685772/

COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: 
https://pubmed.ncbi.nlm.nih.gov/33947605/
.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: 
https://pubmed.ncbi.nlm.nih.gov/34526175/

Lymphadenopathy associated with the COVID-19 vaccine: 
https://pubmed.ncbi.nlm.nih.gov/33786231/

Evolution of lymphadenopathy on PET/MRI
Massive cervical lymphadenopathy following vaccination with COVID-19 
https://pubmed.ncbi.nlm.nih.gov/34601889/

Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021:
https://pubmed.ncbi.nlm.nih.gov/33706861/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: 
https://pubmed.ncbi.nlm.nih.gov/34116295/

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDGfinding: 
https://pubmed.ncbi.nlm.nih.gov/33661328/

A case of cervical lymphadenopathy following COVID-19 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34141500/

Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: 
https://pubmed.ncbi.nlm.nih.gov/33713605/

Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: 
https://pubmed.ncbi.nlm.nih.gov/33685772/

COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: 
https://pubmed.ncbi.nlm.nih.gov/33947605/

Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: 
https://pubmed.ncbi.nlm.nih.gov/34526175/

Lymphadenopathy associated with the COVID-19 vaccine: 
https://pubmed.ncbi.nlm.nih.gov/33786231/

Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/33625301/
.
Massive cervical lymphadenopathy following vaccination with COVID-19 
https://pubmed.ncbi.nlm.nih.gov/34601889/

COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imagingfindings on MRI, CT and PET-CT: 
https://pubmed.ncbi.nlm.nih.gov/34719892/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: 
https://pubmed.ncbi.nlm.nih.gov/34116295/
.
Evolution of Lymphadenopathy at Pet/MRI after COVID-19 vaccination:
https://pubmed.ncbi.nlm.nih.gov/33625301/

体位性頻脈症候群（POTS）

体位性頻脈症候群（POTS）のページを更新

　体位性頻脈症候群（Postural Orthostatic Tachycardia Syndrome（POTS）ポッツと読みます）は、身体が横になっている状態から立っている状態へと動いた時に、心拍数が大きく上昇し、起立不耐症（立位の維持が困難となる症状）を特徴としています。
立ち上がると、立ちくらみや動悸などの症状が現れます。横になると症状がやわらぎます。また立っていない時に、疲労感、運動不耐、胃腸症状などが現れることがあります。慢性的で、就学や就労の制限、QOL低下、身体不自由、経済的困窮になることがあります。

　【原因】

　発症は年齢・性別によらずみられますが、北米では12～50歳の女性に好発する（80%以上）と言われており、発症のきっかけはウイルス感染、身体的外傷、初潮、妊娠、手術の後などが挙げられています。
最近ではコロナワクチン接種後に多く発生しています。

　【症状】

　POTSは立位時に心拍数が大きく上昇し、以下のような症状が現れます（すべての症状が必ず現れるということではありません）
立ちくらみ、めまい
失神前状態、失神
動悸
息切れ
胸痛
振戦（震え）
脱力
目がぼやける
下肢の色調変化（赤紫色）
その他に、以下のような症状が現れることがあります。

頭痛
エネルギー低下、疲労感、倦怠感
胃腸症状（吐き気、腹痛、腹部膨満感、便秘、下痢）
膀胱症状
睡眠障害
ブレインフォグ（集中力・思考力・記憶力の低下）
光・音の過敏症
四肢の冷え・痛み

　【治療法】

　POTSにみられる多彩な症状や臨床的特徴は、患者さんによってちがいがあり、いくつかの病因・病態が考えられています。メカニズムに神経障害性、循環血液量の減少、高アドレナリン、自己免疫などがあるとされていますが、病因・病態はまだ十分に解明されていません。疫学知見、病因・病態の解明、診断・治療法の開発が急務となっています。

COVID-19 mRNAワクチンによる障害報告のレビュー：ギラン・バレー症候群

Dr Mark Trozzi（マーク・トロッツィ博士）がCOVID-19 mRNAワクチンによる障害報告に関する査読済み論文の約1,000件を掲載したサイトを作っています。

1000 peer reviewed articles on “Vaccine” injuries

その中で6番目に多くの件数が報告されている「ギラン・バレー症候群（Guillain-Barre Syndrome;GBS）」の論文リストを転載させていただきます。

体の免疫系が誤って末梢神経系（脳と脊髄の外側にある神経のネットワーク）の一部を攻撃する神経疾患。GBSは、短時間の脱力感を伴うごく軽症のものから、ほとんど壊滅的な麻痺を引き起こし、独立して呼吸することができなくなるものまである。幸いなことに、GBSの重症例であっても、ほとんどの人は最終的に回復する。回復後も、ある程度の脱力が続く人もいます。

掲載論文数: 43

GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: 
https://www.sciencedirect.com/science/article/pii/S2666354621000065

Guillain-Barre syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: 
https://www.sciencedirect.com/science/article/pii/S0303846721004169

Sensory Guillain-Barre syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: 
https://www.sciencedirect.com/science/article/pii/S0165572821002186

Guillain-Barre syndrome after thefirst dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: 
https://www.sciencedirect.com/science/article/pii/S2214250921000998

Guillain-Barre syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: 
https://www.sciencedirect.com/science/article/pii/S0736467921006442

Guillain-Barre syndrome after thefirst injection of ChAdOx1 nCoV-19 vaccine: first report:
https://www.sciencedirect.com/science/article/pii/S0035378721005853

SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https://www.sciencedirect.com/science/article/pii/S2049080121005343

Guillian Barre syndrome after vaccination with mRNA-1273 against COVID-19 
https://pubmed.ncbi.nlm.nih.gov/34477091/

A novel case of bifacial diplegia variant of Guillain-Barre syndrome after vaccination with Janssen COVID-19 
https://pubmed.ncbi.nlm.nih.gov/34449715/

Sensory Guillain-Barre syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: 
https://pubmed.ncbi.nlm.nih.gov/34416410/

Facial diplegia: a rare and atypical variant of Guillain-Barre syndrome and the Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/

Guillain-Barre syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: 
https://pubmed.ncbi.nlm.nih.gov/34548920/

AstraZeneca COVID-19 vaccine and Guillain-Barre syndrome in Tasmania: a causal link: 
https://pubmed.ncbi.nlm.nih.gov/34560365/

COVID-19, Guillain-Barre and vaccineA dangerous mix: 
https://pubmed.ncbi.nlm.nih.gov/34108736/

Guillain-Barre syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: 
https://pubmed.ncbi.nlm.nih.gov/34796417/

Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: 
https://link.springer.com/article/10.1007%2Fs10072-021-05523-5

COVID-19 adenovirus vaccines and Guillain-Barre syndrome with facial palsy: 
https://onlinelibrary.wiley.com/doi/10.1002/ana.26258

Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: 
https://jamanetwork.com/journals/jama/fullarticle/2785009

A case of Guillain-Barre syndrome after P? zer COVID-19vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34567447/

Guillain-Barre syndrome associated with COVID-19 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34648420/

Rate of recurrent Guillain-Barre syndrome after COVID-19 BNT162b2 mRNA vaccine: 
https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708

Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: 
https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext

Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34114256/

Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: 
https://pubmed.ncbi.nlm.nih.gov/34767184/

Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: 
https://pubmed.ncbi.nlm.nih.gov/34644738/

Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: 
https://pubmed.ncbi.nlm.nih.gov/34649856/

A rare case of Guillain-Barre syndrome after COVID-19 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34671572/

Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/

COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: 
https://pubmed.ncbi.nlm.nih.gov/34484780/

Guillain-Barre syndrome after thefirst dose of COVID-19 vaccination: case report; 
https://pubmed.ncbi.nlm.nih.gov/34779385/

Guillain-Barre syndrome after thefirst injection of ChAdOx1 nCoV-19 vaccine: first report: 
https://pubmed.ncbi.nlm.nih.gov/34217513/

A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after? rst dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): 
https://pubmed.ncbi.nlm.nih.gov/34871447/

A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN: 
https://pubmed.ncbi.nlm.nih.gov/34370408/

A rare variant of Guillain-Barre syndrome after vaccination with Ad26.COV2.S: 
https://pubmed.ncbi.nlm.nih.gov/34703690/

Guillain-Barre syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barre syndrome: 
https://pubmed.ncbi.nlm.nih.gov/34810163/

Guillain-Barre syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218

Variant Guillain-Barre syndrome occurring after SARS-CoV-2 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34114269/

Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34722067/

Guillain-Barre syndrome after the? rst dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: 
https://pubmed.ncbi.nlm.nih.gov/33968610/

SARS-CoV-2 vaccines can be complicated not only by Guillain-Barre syndrome but also by distal small fiber neuropathy: 
https://pubmed.ncbi.nlm.nih.gov/34525410/

Clinical variant of Guillain-Barre syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34808658/

Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: 
https://pubmed.ncbi.nlm.nih.gov/34848426/

Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: 
https://pubmed.ncbi.nlm.nih.gov/34261746/

（参考）　コロナワクチンによる様々な脳障害・神経障害（2）